DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-333
Drug: Placebo

First Posted Date: 2008-06-13

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 133

Registration Number: NCT00696904

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: ABT-874
Biological: etanercept
Drug: placebo

First Posted Date: 2008-06-06

Last Posted Date: 2013-01-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 347

Registration Number: NCT00691964

Locations: 🇺🇸
Site Reference ID/Investigator# 8471, Philadelphia, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 9641, Miami, Florida, United States
🇺🇸
Site Reference ID/Investigator# 8464, Boston, Massachusetts, United States

and more 32 locations

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: ABT-089

First Posted Date: 2008-05-30

Last Posted Date: 2013-01-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 117

Registration Number: NCT00686933

Locations: 🇺🇸
Site Reference ID/Investigator# 8319, Virginia Beach, Virginia, United States
🇺🇸
Site Reference ID/Investigator# 8318, Troy, Michigan, United States
🇺🇸
Site Reference ID/Investigator# 8310, Memphis, Tennessee, United States

and more 9 locations

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab

First Posted Date: 2008-05-29

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 100

Registration Number: NCT00686374

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: ABT-874
Drug: Methotrexate

First Posted Date: 2008-05-19

Last Posted Date: 2013-01-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 317

Registration Number: NCT00679731

Locations: 🇦🇹
Site Reference ID/Investigator# 12763, Vienna, Austria
🇨🇦
Site Reference ID/Investigator# 13104, Barrie, Canada
🇸🇪
Site Reference ID/Investigator# 8185, Stockholm, Sweden

and more 40 locations

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Phase 3

Completed

Conditions: Tanner Staging
Gonadotrophin-releasing Hormone (GnRH)
Pediatrics Central Precocious Puberty
Leuprolide Acetate
Suppression of LH
Lupron
Gonadotrophin-releasing Hormone Agonist (GnRHa)
Depot Formulation
Central Precocious Puberty (CPP)
Precocious

Interventions: Drug: Leuprolide Acetate 3 Month Depot

First Posted Date: 2008-04-28

Last Posted Date: 2014-01-09

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 72

Registration Number: NCT00667446

Locations: 🇺🇸
Site Reference ID/Investigator# 14121, Kansas City, Missouri, United States
🇵🇷
Site Reference ID/Investigator# 23182, Bayamon, Puerto Rico
🇵🇷
Site Reference ID/Investigator# 21721, Ponce, Puerto Rico

and more 17 locations

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
Device: CADD-Legacy® 1400 ambulatory infusion pump
Device: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)

First Posted Date: 2008-04-17

Last Posted Date: 2022-12-02

Lead Sponsor: AbbVie

Target Recruit Count: 262

Registration Number: NCT00660673

Locations: 🇺🇸
Univ Maryland School Medicine /ID# 49934, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University /ID# 49937, Baltimore, Maryland, United States
🇺🇸
Charlotte Neurological Service /ID# 49916, Port Charlotte, Florida, United States

and more 58 locations

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Placebo Gel
Drug: Levodopa carbidopa intestinal gel (LCIG)
Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
Drug: Placebo (PBO) oral capsules
Device: CADD-Legacy® 1400 ambulatory infusion pump
Device: PEG tube
Device: J-tube

First Posted Date: 2008-04-17

Last Posted Date: 2015-01-16

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 35

Registration Number: NCT00660387

Locations: 🇺🇸
Site Reference ID/Investigator# 45931, Birmingham, Alabama, United States
🇺🇸
Site Reference ID/Investigator# 45908, Cincinnati, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 45922, Cleveland, Ohio, United States

and more 11 locations

A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M200 (Volociximab), Carboplatin, Paclitaxel

First Posted Date: 2008-04-09

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 33

Registration Number: NCT00654758

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: adalimumab

First Posted Date: 2008-04-01

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT00650156

Locations: 🇨🇳
Site Reference ID/Investigator# 7181, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy